[Exposed] Men Being “Chemically Castrated” For NO Reason?!

For years, men with prostate cancer have been told they need hormone therapy after surgery and radiation.

It’s a treatment that basically chemically castrates them…

It saps energy, destroys their sex lives, and can trigger heart, bone, and cognitive problems.

But new evidence suggests most of these men were enduring these devastating side effects for almost no gain.

Before you or a loved one submits themselves to this brutal treatment, you need to see the evidence they’re not telling you.

A massive meta-analysis, pooling individual patient data from six randomized trials and over 6,000 men, has revealed a startling truth: for the majority of men with low PSA levels after surgery, adding hormone therapy to postoperative radiotherapy does not improve overall survival.

And the numbers are stark.

After 10 years, 83.6% of men survived with radiotherapy alone, compared with 84.3% who also received hormone therapy.

That’s statistically insignificant. Basically, no difference.

In plain English: you endure months of hormone treatment, with its crippling side effects, and you’re almost no more likely to be alive a decade later.

The only men who saw a measurable survival benefit were those with higher PSA levels.

For example, for PSA above 1.00 ng/mL, the reduction was 31%. But this is just a fraction of guys. For most men, once you’ve had prostate surgery and radiation, your PSA plummets.

And for men with PSA at or below 0.5 ng/mL—the majority—there was no survival advantage, even with long-term therapy.

Why does this matter?

Hormone therapy is brutal. It can drain men of strength, destroy sexual function, accelerate bone loss, and worsen heart health.

And for most men with low PSA after surgery, the data show you can skip it without sacrificing survival.

Experts are now urging a major rethink. Amar Kishan, MD, of UCLA, emphasizes that “by safely omitting hormone therapy in these patients, we can spare months of treatment that may substantially affect quality of life without extending survival.”

Meanwhile, others note that careful patient selection—based on PSA levels and tumor biology—can help focus hormone therapy only on those who truly need it.

This is a wake-up call for men facing prostate cancer treatment: if your PSA is low after surgery, hormone therapy might not just be unnecessary—it could be actively harming you.

The medical community is finally catching up to what the data have been telling us: more treatment is not always better, and survival should never come at the cost of life itself.

Bottom line: Before agreeing to hormone therapy after prostate surgery, ask your doctor if you really need it. For most men, skipping it won’t shorten life—but will save health, strength, and dignity.

To knowing what really works (and what doesn’t),

Ray Thatcher
Research Director, Health Sciences Institute

Sources:

• Bassett, M. (2026, February 27). Study questions use of prostate cancer hormone therapy in certain cases—Adding hormone therapy to postoperative radiotherapy did not improve OS for most patients. MedPage Today. https://www.medpagetoday.com/meetingcoverage/mgucs/120075
• Kishan, A. U., Sun, Y., Parker, C. C., Sargos, P., Sydes, M. R., Chabaud, S., … et al. (2026). Hormone therapy use and duration with postoperative radiotherapy for recurrent prostate cancer: An individual patient data meta-analysis. The Lancet. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00137-6/fulltext